|Prof McMillan is a cancer researcher interested in the infectious causes of cancer. Nearly ⅓ of all cancers are caused by viruses, bacteria and other microorganisms. He is an internationally recognised expert in the area of human papillomavirus, gene editing and gene silencing. He has over 90 publications and has had continuous NHRMC funding for 22 years. He has graduated over 40 Masters or Honours students and 22 PhD students.|
- Nitschinsk, K., Clarke, D., Idris, A., & McMillan, N. (2018). RNAi Targeting of Human Metapneumovirus P and N Genes Inhibits Viral Growth. Intervirology, 1–6.
- Nitschinsk, K., Idris, A., & McMillan, N. (2018). Patient derived xenografts as models for head and neck cancer. Cancer Letters, 434, 114–119.
- Shaikh, M., Idris, A., Johnson, N., Fallaha, S., Clarke, D., Martin, D., … McMillan, N. (2018). Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers. Oral Oncology, 86, 105–112.
- Gytz, H., Hansen, M. F., Skovbjerg, S., Kristensen, A. C. M., Horlyck, S., Jensen, M. B., … Martensen, P. M. (2017). Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins. Biology of the Cell, 109, 1–19.
- Jubair, L., & McMillan, N. (2017). The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System. Molecular Therapy: Nucleic Acids, 8, 56–63.
- Li, X., Tian, R., Gao, H., Yang, Y., Williams, B., Gantier, M. P., … Hu, Y. (2017). Identification of a histone family gene signature for predicting the prognosis of cervical cancer patients. Scientific Reports, 7, 16495–1–16495–13.
- Martin, D., Fallaha, S., Proctor, M., Stevenson, A., Perrin, L., McMillan, N., & Gabrielli, B. (2017). Inhibition of Aurora A and Aurora B is required for the sensitivity of HPV-driven cervical cancers to Aurora kinase inhibitors. Molecular Cancer Therapeutics, 16(9), 1934–1941.
- Shaikh, M., Clarke, D., Johnson, N., & McMillan, N. (2017). Can gene editing and silencing technologies play a role in the treatment of head and neck cancer? Oral Oncology, 68, 9–19.
- Shaikh, M., Khan, A. I., Sadat, A., Chowdhury, A. H., Jinnah, S. A., Gopalan, V., … Johnson, N. (2017). Prevalence and types of high-risk human papillomaviruses in head and neck cancers from Bangladesh. BMC Cancer, 17, 792–1–792–11.
- Tayyar, Y., Jubair, L., Fallaha, S., & McMillan, N. (2017). Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data. Critical Reviews in Oncology/Hematology, 119, 59–65.
- Hussein, W., Liu, T.-Y., Jia, Z., McMillan, N., Monteiro, M. J., Toth, I., & Skwarczynski, M. (2016). Multiantigenic peptide–polymer conjugates as therapeutic vaccines against cervical cancer. Bioorganic & Medicinal Chemistry, 24(18), 4372–4380.
- Sheng, Y., He, Y., Hasnain, S., Wang, R., Tong, H., Clarke, D., … McGuckin, M. (2016). MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target. Oncogene, 1–14.
- Singhania, R., Pavey, S., Payne, E., Gu, W., Clancy, J., Jubair, L., … McMillan, N. (2016). Short interfering RNA induced generation and translation of stable 5 mRNA cleavage intermediates. Biochimica et Biophysica Acta, 1859(8), 1034–1042.
- Bokhari, F., Ranall, M. V., Oo, Z. Y., Stevenson, A. J., Wang, W., Murrell, M., … McMillan, N. (2015). Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer. Molecular Cancer Therapeutics, 14(12), 2753–2761.
- Clarke, D., & McMillan, N. (2015). Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies. Current Drug Delivery, 12, 86–97.
- Gu, W., McMillan, N., & Yu, C. (2015). Silencing of E6/E7 Expression in Cervical Cancer Stem-Like Cells. In Cervical Cancer: Methods and Protocols (pp. 173–182).
- Liu, T.-Y., Giddam, A. K., Hussein, W., Jia, Z., McMillan, N., Monteiro, M., … Skwarczynski, M. (2015). Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model. Current Drug Delivery, 12(1), 3–8.
- Liu, T.-Y., Hussein, W., Giddam, A. K., Jia, Z., Reiman, J., Zaman, M., … Skwarczynski, M. (2015). Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. Journal of Medicinal Chemistry, 58(2), 888–896.
- Moyle, P. M., Dai, W., Liu, T.-Y., Hussein, W., Maruthayanar, P., Wells, J. W., … Toth, I. (2015). Combined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors. Bioorganic & Medicinal Chemistry Letters, 25(23), 5570–5575.
- Shaikh, M., McMillan, N., & Johnson, N. (2015). HPV-associated head and neck cancers in the Asia Pacific: A critical literature review & meta-analysis. Cancer Epidemiology, 39(6), 923–938.
- Ardana, A., Whittaker, A. K., McMillan, N., & Thurecht, K. J. (2014). Polymeric siRNA delivery vectors: knocking down cancers with polymeric-based gene delivery systems. Journal of Chemical Technology and Biotechnology, 1–13.
- Clarke, D., & McMillan, N. (2014). Cell specific therapy on target. Nature Nanotechnology, 9(8), 568–569.
- Haigh, O., Depelsenaire, A. C. I., Meliga, S. C., Yukiko, S. R., McMillan, N., Frazer, I. H., & Kendall, M. A. F. (2014). CXCL1 gene silencing in skin using liposome-encapsulated siRNA delivered by microprojection array. Journal of Controlled Release, 194, 148–156.
- Khairuddin, N., Blake, S. J., Firdaus, F., Steptoe, R. J., Behlke, M. A., Hertzog, P. J., & McMillan, N. (2014). In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours. Immunology and Cell Biology, 92(2), 156–163.
- Wu, S. Y., Yang, X., Gharpure, K. M., Hatakeyama, H., Egli, M., McGuire, M. H., … al, et. (2014). 2-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 5, 3459–1–3459–12.
- Burgess, M., Gill, D., Singhania, R., Cheung, C., Chambers, L., Renyolds, B. A., … McMillan, N. (2013). CD62L as a therapeutic target in chronic lymphocytic leukemia. Clinical Cancer Research, 19(20), 5675–5685.
- Liu, T.-Y., Hussein, W. M., Jia, Z., Ziora, Z. M., McMillan, N., Monteiro, M. J., … Skwarczynski, M. (2013). Self-adjuvanting Polymer-peptide Conjugates as Therapeutic Vaccine Candidates against Cervical Cancer. Biomacromolecules, 14(8), 2798–2806.
- McCaskill, J. L., Marsh, G., Monaghan, P., Wang, L.-F., Doran, T., & McMillan, N. (2013). Potent Inhibition of Hendra Virus Infection via RNA Interference and Poly I:C Immune Activation. PLoS One, 8(5), e64360–1–e64360–9.
- McCaskill, J. L., Wu, S., Khairuddin, N., & McMillan, N. (2013). Lowering the sirna delivery barrier: Alginate scaffolds and immune stimulation. In Nanotechnology for the Delivery of Therapeutic Nucleic Acids (pp. 193–216).
- McCaskill, J., Singhania, R., Burgess, M., Allavena, R., Wu, S., Blumenthal, A., & McMillan, N. (2013). Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Molecular Therapy: Nucleic Acids, 2, e96–1–e96–10.
- Plummer, P., Lambrechts, R., Taft, R. J., Vider, J., Sax, M., Umer, B., … Mellick, A. (2013). MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells. Cancer Research, 73(1), 341–352.
- Blake, S. J., Bokhari, F. F., & McMillan, N. (2012). RNA Interference for Viral Infections. Current Drug Targets, 13(11), 1411–1420.
- Burgess, M., Cheung, C., Chambers, L., Ravindranath, K., Minhas, G., Knop, L., … Gill, D. (2012). CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leukemia and Lymphoma, 53(10), 1988–1998.
- Chen, J., McMillan, N., & Gu, W. (2012). Intra-tumor injection of lentiviral-vector delivered shRNA targeting human papillomavirus E6 and E7 oncogenes reduces tumor growth in a xenograft cervical cancer model in mice. Journal of Solid Tumors, 2(4), 1–7.
- Khairuddin, N., Gantier, M., Blake, S., Wu, S., Behlke, M., Williams, B., & McMillan, N. (2012). siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunology and Cell Biology, 90(2), 187–196.
- Lane, S., Gill, D., McMillan, N., Saunders, N., Murphy, R., Spurr, T., … Mollee, P. (2012). Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia and Lymphoma, 53(6), 1077–1083.
- Singhania, R., Khairuddin, N., Clarke, D., & McMillan, N. (2012). RNA Interference for the Treatment of Papillomavirus Disease. The Open Virology Journal, 6, 204–215.
- Tan, J. H., McMillan, N., Payne, E., Alexander, C., Heath, F., Whittaker, A. K., & Thurecht, K. J. (2012). Hyperbranched polymers as delivery vectors for oligonucleotides. Journal of Polymer Science. Part A, Polymer Chemistry, 50(13), 2585–2595.
- Truong, N. P., Jia, Z., Burgess, M., Payne, L., McMillan, N., & Monteiro, M. J. (2012). Self-Catalyzed Degradable Cationic Polymer for Release of DNA. Biomacromolecules, 12(10), 3540–3548.
- Waddell, N., Stein, S., Wagner, S., Bennett, I., Djougarian, A., Melana, S., … Francis, G. (2012). Morphological and molecular analysis of a breast cancer cluster at the ABC Studio in Toowong. Pathology, 44(5), 469–472.
- Antonsson, A., Spurr, T. P., Chen, A. C., Francis, G., McMillan, N., Saunders, N. A., … Bennett, I. C. (2011). High Prevalence of Human Papillomaviruses in Fresh Frozen Breast Cancer Samples. Journal of Medical Virology, 83(12), 2157–2163.
- Chen, A. C.-H., Waterboer, T., Keleher, A., Morrison, B., Jindal, S., McMillan, D., … Antonsson, A. (2011). Human Papillomavirus in Benign Prostatic Hyperplasia and Prostatic Adenocarcinoma Patients. Pathology and Oncology Research, 17, 613–617.
- Gu, W., Payne, E., Sun, S., Burgess, M., & McMillan, N. (2011). Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene Therapy: the journal of cancer gene and cellular therapies, 18, 219–227.
- Gu, W., Yeo, E., McMillan, N., & Yu, C. (2011). Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Therapy, 18(12), 897–905.
- Singhania, A., Y.Wu, S., & McMillan, N. (2011). Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. Journal of Drug Delivery, 2011, 192562–1–192562–7.
- Truong, N. P., Jia, Z., Burges, M., McMillan, N., & Monteiro, M. (2011). Self-Catalyzed Degradation of Linear Cationic Poly(2-dimethylaminoethyl acrylate) in Water. Biomacromolecules, 12(5), 1876–1882.
- Wu, S. Y., Chang, H.-I., Burgess, M., & McMillan, N. (2011). Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. Journal of Controlled Release, 155(3), 418–426.
- Wu, S. Y., Singhania, A., Burgess, M., Putral, L. N., Kirkpatrick, C., Davies, N. M., & McMillan, N. (2011). Systemic Delivery of E6/7 SiRNA Using Novel Lipidic Particles and Its Application with Cisplatin in Cervical Cancer Mouse Models. Gene Therapy, 18, 14–22.
- Chen, A. C.-H., Keleher, A., Kedda, M.-A., Spurdle, A. B., McMillan, N., & Antonsson, A. (2009). Human papillomavirus DNA detected in peripheral blood samples from healthy Australian male blood donors. Journal of Medical Virology, 81(10), 1792–1796.
- Gu, W., Cochrane, M., Leggatt, G. R., Payne, E., Choyce, A., Zhou, F., … McMillan, N. (2009). Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses. Proceedings of the National Academy of Sciences, 106(20), 8314–8319.
- Hsu, J. C., Chen, A. H., Keleher, A., McMillan, N., & Antonsson, A. (2009). Shared and persistent asymptomatic cutaneous human papillomavirus infections in healthy skin. Journal of Medical Virology, 81(8), 1444–1449.
- Chen, J., & McMillan, N. (2008). Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. Cancer Biology & Therapy, 7(2), 174–179.
- Chen, J., McMillan, N., Irving, A., & Gu, W. (2007). Future of RNAi-based therapies for human papillomavirus-associated cervical cancer. Future Virology, 2(6), 587–595.
- Clarke, D., Irving, A., Lambley, E., Payne, E., & McMillan, N. (2005). A novel method for screening viral interferon-resistance genes. Journal of Interferon & Cytokine Research, 24(8), 470–477.
- (2018). High throughput label-free interaction analysis - from fragments to drug discovery
- (2018). NHMRC Standard Equipment Grant
- (2017). Griffith University Personalized Medicine Program: a proposal for advanced cancer diagnosis and drug development facility
- (2016). Aurora A as a novel therapeutic target for HPV-driven cancers
- (2016). Griffith University-GCUH Personalised Medicine Program (a novel facility for advanced cancer treatment and drug development)
- (2015). NHMRC Standard Equipment Grant 2015
- (2015). Novel therapeutic targets for HPV-driven cancers
- (2014). Live Animal Imaging for Advanced Therapy Development
- (2013). Nanoparticle mucosal delivery systems for siRNA-based cancer therapies
- (2013). Purchase of state-of-art multi-well plate reader and expansion of the Oxygraph
- (2013). Stealth liposomes and siRNA for the treatment of respiratory viral infections
- (2013). Targeting Tumour Angiogenesis in Breast Cancer by Altering MicroRNA Signalling
- (2013). Tri-gas hypoxic incubators for regulated oxygen levels: Thermo Scientific Heracell 150i
- (2012). Novel Antivirals for the treatment of Hendravirus Infection.
- (2012). RNAi and the Immune System
- (2011). Development of nanoparticle mucosal delivery systems for siRNA-based cancer therapies
Teacher, In Person, Gold Coast Campus, Semester 1, 2016.
Teacher, In Person, Gold Coast Campus, Semester 1, 2018.
Teacher, In Person, Gold Coast Campus, Semester 1, 2017.
Teacher, In Person, Gold Coast Campus, Semester 2, 2017.
Teacher, In Person, Gold Coast Campus, Semester 1, 2016.
Teacher, In Person, Gold Coast Campus, Semester 2, 2016.
Convenor, In Person, Gold Coast Campus, Semester 1, 2015.
Teacher, In Person, Gold Coast Campus, Semester 1, 2015.
Teacher, In Person, Gold Coast Campus, Semester 2, 2015.
Convenor, In Person, Gold Coast Campus, Semester 1, 2014.
Teacher, In Person, Gold Coast Campus, Semester 1, 2014.
Teacher, In Person, Gold Coast Campus, Semester 2, 2014.
Convenor, In Person, Gold Coast Campus, Semester 1, 2013.
Teacher, In Person, Gold Coast Campus, Semester 1, 2013.
Convenor, In Person, Gold Coast Campus, Semester 1, 2012.
Teacher, In Person, Gold Coast Campus, Semester 1, 2012.
Track Record PROF NIGEL MCMILLAN
Overview and Current Position. Prof McMillan is a cancer biologist whose research has focused on the interaction between viruses and host cells and novel delivery systems for siRNA. Following his postdoctoral training in the USA (10 papers/356 citations), he established his own laboratory at the University of Queensland (UQ) in 1994 and was appointed a Research Fellow (1998), a Senior Research Fellow (2001), and a Principal Research Fellow in 2009. He is now Professor, Deputy Head of the School of Medical Science, and Director of the Molecular Basis of Disease Program, one of 6 research programs within Griffith Health Institute. This program has over 150 scientists.
Summary of research interests: Prof McMillan is internationally recognized as an expert in the area of RNA interference therapy with major contributions over the last 10 years in the areas of delivery and the interface between RNAi and the immune system. Clinically his lab is interested in treating viral infections, particularly those that result in cancer, such as human papillomavirus. The laboratory takes a multidisciplinary approach to its research work and we have a diverse set of national and international collaborators in the areas of nanoparticle system development, immunology, and cancer biology. This includes international biotechnology companies with whom we have licensed our patents and for whom we undertake contract research. His laboratory has expertise covering the disciplines of molecular biology, cell biology, virology and immunology and focuses on diseases caused by the human papillomavirus. Recent success in nanoparticle delivery has led to an active research program in respiratory viral infections, specifically RSV, Hendravirus and Influenza. Prof McMillan is currently CI on 2 NHMRC grants.
Funding Record. Prof McMillan has had continuous NHMRC grant funding since establishing his laboratory in 1996, and has attracted over $13m in competitive grant funding from national sources (NHMRC, ARC Discovery, Cancer Council, Leukaemia Foundation, Uniseed, Uniquest, and ARC Linkage).
Publication record: Prof McMillan has published 33 papers and reviews since 2010. Publications are in leading journals including papers in PNAS, Clinical Cancer Research, Journal of Virology, Virology, Molecular Therapy, Gene Therapy, Cancer Gene Therapy, Pharm. Research, Journal of Controlled Release, Nature Nanotechnology and Nature Communications. He has >2400 total citations and an average of 37 citations per paper. His paper on the discovery of the HPV receptor (J Virology, 71(3), 2449-2456, 2007) has 332 citations. He has 3 patents, in the areas of siRNA, HPV and novel leukaemia therapies. One is licensed to Alnylam, the leading RNAi company and a major US biotechnology company in Boston.
Leadership and Profile. Prof McMillan has been invited to present work at both national and international meetings. He has received invitations to be Plenary and Keynote speakers at international meetings including RNAi Asia 2010, RNAi World Congress 2011, and the 2nd RNAi Research and Therapeutics Conference. He has been invited to speak at Lorne, Australian Health and Medical Research Congress, OzBio, Endocrine Society, TERMIS, Australian Virology Society, ASM etc. He has served on grant review panels for the European Union Framework 7 and panels for the Queensland Cancer Fund and reviewed grants for the NHMRC, ARC, HRC-NZ, IUAC, RGC Hong Kong and ARC. He is a member of the ARC ERA 2015 evaluation academy. He has been the Conference Convener for 5 national meetings. Prof McMillan was a founding member and Deputy Director of the UQ Diamantina Institute and was instrumental in establishing the RNA Network of Australasia and the Australasian Virology Society, serving as national secretary for both. He is currently Vice-President of the Australasian Virology Society.
Research Training/Mentoring: Prof McMillan has been the supervisor for 18 PhD. candidates, all of whom have gone on to postdoctoral training here or overseas once completed. He has trained 31 Hons or Masters students.
PhD Doctor of Philosophy, University of Otago 1991
BScHons Bachelor Of Science With Honours, University of Otago 1987
President, Australasian Virology Society 2016 - Present